Literature DB >> 33884217

Dantrolene-Induced Hepatitis: A Rare Culprit in the PICU.

Divij Pasrija1, Shilpi Gupta2, Amanda Hassinger1.   

Abstract

Dantrolene is used for reversal of malignant hyperthermia and for improvement in spasticity following stroke which are Food and Drug Administration-approved indications. It is an infrequently used medication in the pediatric intensive care unit and is usually continued from the operating room or sedation suite after suspicion for malignant hyperthermia, secondary to other medications and anesthetic agents. Hepatitis has been described as a side effect of the medication after prolonged use and at doses of more than 100 mg/d mainly in adults. We described in this case report a patient in which the drug was used for sympathetic overactivity in the PICU and development of asymptomatic hepatitis on day 3 after starting the medication at a dose much lower than previously described. Thieme. All rights reserved.

Entities:  

Keywords:  dantrolene; hepatitis; spasticity; toxicity

Year:  2020        PMID: 33884217      PMCID: PMC8052104          DOI: 10.1055/s-0040-1710496

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  7 in total

1.  Treatment of spastic cerebral-palsied children with sodium dantrolene.

Authors:  E Denhoff; S Feldman; M G Smith; H Litchman; W Holden
Journal:  Dev Med Child Neurol       Date:  1975-12       Impact factor: 5.449

2.  Safety of low-dose oral dantrolene sodium on hepatic function.

Authors:  Jung Yoon Kim; Sewoong Chun; Moon Suk Bang; Hyung-Ik Shin; Shi-Uk Lee
Journal:  Arch Phys Med Rehabil       Date:  2011-09       Impact factor: 3.966

3.  Dantrolene sodium and hepatic injury.

Authors:  C H Chan
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

Review 4.  Applying mechanisms of chemical toxicity to predict drug safety.

Authors:  F Peter Guengerich; James S MacDonald
Journal:  Chem Res Toxicol       Date:  2007-02-16       Impact factor: 3.739

Review 5.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

6.  Dantrolene-associated hepatic injury. Incidence and character.

Authors:  R Utili; J K Boitnott; H J Zimmerman
Journal:  Gastroenterology       Date:  1977-04       Impact factor: 22.682

7.  Hepatitis from dantrolene sodium.

Authors:  S P Wilkinson; B Portmann; R Williams
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.